Ax­some ex­pects mi­graine drug to be re­ject­ed as man­u­fac­tur­ing is­sues arise

A New York-based bio­phar­ma com­pa­ny now ex­pects a re­jec­tion from the FDA for its po­ten­tial mi­graine drug as it’s fac­ing man­u­fac­tur­ing ques­tions.

Ax­some Ther­a­peu­tics, ac­cord­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER